Tempest Therapeutics, Inc. (TPST)
| Market Cap | 16.94M -64.5% |
| Revenue (ttm) | n/a |
| Net Income | -40.47M |
| EPS | -4.56 |
| Shares Out | 15.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,978 |
| Open | 1.092 |
| Previous Close | 1.080 |
| Day's Range | 1.040 - 1.100 |
| 52-Week Range | 0.840 - 12.230 |
| Beta | -1.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About TPST
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr... [Read more]
Financial Performance
Financial StatementsNews
Tempest Therapeutics files to sell 8.91M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.91M shares of common stock. The company is not selling any…
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patie...
Tempest Therapeutics Earnings release: Q2 2026
Tempest Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Tempest Therapeutics Quarterly report: Q2 2026
Tempest Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen rec...
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Slides: Corporate presentation
Tempest Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen rec...
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics registers to sell 2.43M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.43M shares of common stock. The company is not selling any…
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on June 26, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake R...
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therap...
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)
Tempest Therapeutics Earnings release: Q1 2026
Tempest Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Tempest Therapeutics Quarterly report: Q1 2026
Tempest Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest Therapeutics Slides: Corporate presentation
Tempest Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest Therapeutics provides update on development of TPST-2003
Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed...